

Special Issue

Innovative Perspectives in Ocular Drug Research

Message from the Guest Editor

This Special Issue, “Innovative Perspectives in Ocular Drug Research”, aims to bring together high-quality contributions exploring emerging concepts, rediscovered activities, and functional reassessments of ophthalmic compounds, formulations, and delivery strategies.

Beyond the development of new drug delivery systems, topics of interest include, but are not limited to: novel biological effects; innovative analytical methods; mechanistic insights; repurposing or functional reassessment of existing ophthalmic formulations; protective or bioactive responses to environmental stressors; and advanced in vitro or ex vivo models capable of reproducing relevant ocular conditions.

Studies addressing drug–tissue interactions, as well as computational or imaging approaches in ocular pharmacology, are also encouraged. Original research papers, reviews, and methodological studies that advance contemporary ocular drug science are welcome.

Guest Editor

Dr. Susi Burgalassi
Department of Pharmacy, University of Pisa, 56126 Pisa, Italy

Deadline for manuscript submissions

31 May 2026



Scientia Pharmaceutica

an Open Access Journal
Published by MDPI

Impact Factor 2.5
CiteScore 4.6



mdpi.com/si/263143

Scientia Pharmaceutica
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
scipharm@mdpi.com

[mdpi.com/journal/
scipharm](https://mdpi.com/journal/scipharm)





Scientia Pharmaceutica

an Open Access Journal
Published by MDPI

Impact Factor 2.5
CiteScore 4.6



[mdpi.com/journal/
scipharm](https://mdpi.com/journal/scipharm)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Helmut Viernstein
Division of Pharmaceutical Technology and Biopharmaceutics,
University of Vienna, Josef-Holaubek-Platz 2, 1090 Vienna, Austria

Author Benefits

High Visibility:

indexed within Scopus, ESCI (Web of Science), Embase,
CAPlus / SciFinder, and other databases.

Journal Rank:

CiteScore - Q2 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is
provided to authors approximately 22.8 days after
submission; acceptance to publication is undertaken in 3.1
days (median values for papers published in this journal in
the second half of 2025).